Does semaglutide cause dizziness? Yes, it can. In Wegovy's pooled adult weight-loss trials, about 8 in 100 people reported dizziness, compared with 4 in 100 receiving placebo, an inactive treatment. Most people did not report it.
Feeling dizzy after a shot doesn't explain why it happened. Fluid loss, low blood sugar, falling blood pressure, and changes in eating can all matter. Fainting, chest pain, or new weakness or speech trouble needs urgent attention.
Does semaglutide cause dizziness in the labels?
The Wegovy prescribing information, marked “Revised: 06/2026,” includes dizziness in its side-effect tables. The Ozempic injection prescribing information, marked “Revised: 05/2026,” mentions it separately from the common-reaction table.
| Source and trial setting | Semaglutide | Placebo |
|---|---|---|
| Wegovy 2.4 mg, pooled adult trials lasting up to 68 weeks | 8% | 4% |
| Wegovy 7.2 mg, separate 72-week higher-dose trials | 6% | 1% |
| Wegovy 2.4 mg comparison group in those higher-dose trials | 5% | 1% |
| Ozempic injection, listed among other reactions | More than 0.4%; no exact dizziness rate supplied | No dizziness rate supplied |
The higher-dose table includes dizziness on standing. These are different trial groups, so the rows don't establish that one dose causes less dizziness than another.
Ozempic has no dizziness row in its common-reaction table. That isn't the same as saying dizziness never happens. Nor does “more than 0.4%” mean exactly 0.4%. The label gives no matching placebo percentage for that symptom.
These numbers count people who reported dizziness during a trial. They don't say how often someone felt dizzy each week or how long an episode lasted. Head pain is a separate symptom; the guide to semaglutide and headaches covers that question.
Fluid loss can make someone feel faint
Vomiting and diarrhea can leave the body short of fluid. Dehydration means that fluid shortage, and it can cause lightheadedness, the feeling that fainting might follow. MedlinePlus describes the connection.
The Ozempic label calls its warning “Acute Kidney Injury Due to Volume Depletion.” In plain words, fluid loss from vomiting or diarrhea can lead to sudden kidney injury; some reported cases needed dialysis. Most reported cases followed stomach or bowel symptoms that led to dehydration. Wegovy carries the same warning.
Dizziness alongside repeated vomiting, difficulty keeping fluids down, or much less urine deserves prompt medical assessment. Severe dehydration can also bring confusion, fainting, and a rapid heartbeat. A smaller appetite doesn't make those signs routine.
Feeling faint also matters on a donation day; giving blood while taking semaglutide explains how donor centers screen.
Low blood sugar depends on the medication list
Hypoglycemia means low blood sugar. Both labels warn that its risk rises with insulin or a sulfonylurea, a diabetes medicine that prompts insulin release. Dizziness with shaking, sweating, hunger, or confusion makes that possibility especially relevant.
A dizzy feeling alone cannot establish a low glucose reading. The prescriber considers symptoms, available measurements, and the full diabetes-treatment plan.
As of October 1, 2026, the day this article was written, a study first published July 26 adds useful context. SUSTAIN OPTIMIZE, in Diabetes, Obesity and Metabolism, followed 573 adults with type 2 diabetes and overweight for 40 weeks. Researchers compared semaglutide plus planned reductions in long-acting insulin with insulin treatment alone. Severe lows, episodes needing another person's help, occurred in both groups, though fewer participants reported them with the semaglutide strategy.
The study wasn't sized to settle that comparison. The finding reinforces why the whole medication plan matters, rather than providing a recipe for changing insulin.
Eating less, blood pressure, and heartbeat changes
Eating patterns belong in the conversation too. In a 2021 trial by Friedrichsen and colleagues in Diabetes, Obesity and Metabolism, 72 adults received semaglutide or placebo for 20 weeks. At a test lunch, energy intake was 35% lower with semaglutide. That was one measured meal, not proof that inadequate food caused dizziness.
A clinician may ask whether smaller portions have become skipped meals and whether drinking has fallen too. Reduced intake is a clue to investigate, not a diagnosis of low blood sugar.
Blood pressure can fall during weight loss. The Wegovy label reports that low-pressure reactions were more frequent in people also taking blood-pressure medicines. In its weight-reduction trials, low-blood-pressure reactions were reported in 1.3% on Wegovy versus 0.4% on placebo, and fainting in 0.8% versus 0.2%. Some followed digestive symptoms and fluid loss. Orthostatic hypotension means blood pressure dropping on standing; that pattern can help explain a brief faint feeling. Semaglutide and blood pressure covers the wider evidence. Changes to those medicines belong to the prescriber.
Heartbeat changes need their own assessment. Both labels describe small average pulse increases, but an average doesn't explain an individual's dizzy spell. Palpitations mean feeling a pounding, fluttering, or racing heartbeat. The separate guide to semaglutide and heart rate explains what clinicians watch.
When dizziness needs urgent care
Dizziness with chest pain, trouble breathing, fainting, or new weakness or speech trouble needs urgent medical assessment. Sudden one-sided weakness or difficulty speaking can signal a stroke; emergency care through 911 is appropriate. MedlinePlus lists these emergency warning signs.
A spinning sensation, called vertigo, differs from feeling faint. Inner-ear conditions and other illnesses can cause it. Starting semaglutide doesn't rule those out.
For recurring or worsening dizziness, the useful details are when it began, whether standing triggers it, and what other symptoms appear. A provider may assess blood pressure, blood sugar, hydration, or heart rhythm. An online follow-up message isn't a substitute for emergency care.
Would tirzepatide avoid the dizziness?
There is no assurance it would. Tirzepatide is another prescription option a provider might consider, but its Zepbound label also describes fluid-loss-related kidney injury, low blood pressure, and low blood sugar.
The guide to tirzepatide and hypoglycemia explains that medicine's own evidence. If dizziness reflects insulin, fluid loss, or another illness, choosing a different weight-management medicine doesn't automatically address it. The cause comes first in the provider's review.
What a prescription review adds
The review starts with symptom timing, recent medication changes, food and fluid intake, and any blood-pressure or glucose readings already available. A clinician decides what needs examination or testing and sets the actual treatment plan.
Through Promise, semaglutide is dispensed as a compounded medication, prepared by a pharmacy for a prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Brand-trial percentages cannot establish an exact dizziness rate for a compounded preparation. As of October 1, 2026, the day this article was written, FDA's compounding guidance explains that these preparations don't undergo its safety, effectiveness, and quality review before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
